This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Emini, E A Articles by Putney, S D Search for Related Content PubMed PubMed Citation Articles by Emini, E A Articles by Putney, S D

Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees.

Merck, Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486.

ABSTRACT

This study was undertaken to establish whether antibody directed against the human immunodeficiency virus type 1 (HIV-1) principal gp120 type-specific neutralization determinant can abolish the infectivity of HIV-1 in chimpanzees. Challenge inocula of the IIIb virus isolate were mixed in vitro with either immunoglobulin G (IgG) from an uninfected chimpanzee, nonneutralizing IgG from an HIV-seropositive human, a virus-neutralizing murine monoclonal antibody directed against the HIV-1 IIIb isolate, or virus-neutralizing IgG from a chimpanzee infected with the IIIb isolate. Both neutralizing antibodies were directed against the principal neutralization determinant of the challenge isolate. Establishment of infection following inoculation of each virus-antibody mixture into chimpanzees was assessed by virus-specific antibody development and by virus isolation. No protective effect was noted either with the control IgG or with the nonneutralizing anti-HIV IgG. By contrast, the polyclonal chimpanzee virus-neutralizing IgG prevented HIV-1 in vivo infection, while the neutralizing monoclonal antibody notably decreased the infectivity of the challenge virus. Hence, antibody to the gp120 principal neutralization determinant is able both to prevent HIV-1 infection in vitro and to inhibit infection in vivo.

This article has been cited by other articles:

• van den Brink, E. N., ter Meulen, J., Cox, F., Jongeneelen, M. A. C., Thijsse, A., Throsby, M., Marissen, W. E., Rood, P. M. L., Bakker, A. B. H., Gelderblom, H. R., Martina, B. E., Osterhaus, A. D. M. E., Preiser, W., Doerr, H. W., de Kruif, J., Goudsmit, J. (2005). Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus. J. Virol. 79: 1635-1644 [Abstract] [Full Text]  
• Verrier, F., Nadas, A., Gorny, M. K., Zolla-Pazner, S. (2001). Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6. J. Virol. 75: 9177-9186 [Abstract] [Full Text]  
• ENSHELL-SEIJFFERS, D., SMELYANSKI, L., VARDINON, N., YUST, I., GERSHONI, J. M. (2001). Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals. FASEB J. 15: 2112-2120 [Abstract] [Full Text]  
• Etemad-Moghadam, B., Sun, Y., Nicholson, E. K., Karlsson, G. B., Schenten, D., Sodroski, J. (1999). Determinants of Neutralization Resistance in the Envelope Glycoproteins of a Simian-Human Immunodeficiency Virus Passaged In Vivo. J. Virol. 73: 8873-8879 [Abstract] [Full Text]  
• Robert-Guroff, M., Kaur, H., Patterson, L. J., Leno, M., Conley, A. J., McKenna, P. M., Markham, P. D., Richardson, E., Aldrich, K., Arora, K., Murty, L., Carter, L., Zolla-Pazner, S., Sinangil, F. (1998). Vaccine Protection against a Heterologous, Non-Syncytium-Inducing, Primary Human Immunodeficiency Virus. J. Virol. 72: 10275-10280 [Abstract] [Full Text]  
• Etemad-Moghadam, B., Karlsson, G. B., Halloran, M., Sun, Y., Schenten, D., Fernandes, M., Letvin, N. L., Sodroski, J. (1998). Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys. J. Virol. 72: 8437-8445 [Abstract] [Full Text]  
• Zolla-Pazner, S., Lubeck, M., Xu, S., Burda, S., Natuk, R. J., Sinangil, F., Steimer, K., Gallo, R. C., Eichberg, J. W., Matthews, T., Robert-Guroff, M. (1998). Induction of Neutralizing Antibodies to T-Cell Line-Adapted and Primary Human Immunodeficiency Virus Type 1 Isolates with a Prime-Boost Vaccine Regimen in Chimpanzees. J. Virol. 72: 1052-1059 [Abstract] [Full Text]  
• Smith, A. D., Geisler, S. C., Chen, A. A., Resnick, D. A., Roy, B. M., Lewi, P. J., Arnold, E., Arnold, G. F. (1998). Human Rhinovirus Type 14:Human Immunodeficiency Virus Type 1 (HIV-1) V3 Loop Chimeras from a Combinatorial Library Induce Potent Neutralizing Antibody Responses against HIV-1. J. Virol. 72: 651-659 [Abstract] [Full Text]  
• Okamoto, Y., Eda, Y., Ogura, A., Shibata, S., Amagai, T., Katsura, Y., Asano, T., Kimachi, K., Makizumi, K., Honda, M. (1998). In SCID-hu Mice, Passive Transfer of a Humanized Antibody Prevents Infection and Atrophic Change of Medulla in Human Thymic Implant due to Intravenous Inoculation of Primary HIV-1 Isolate. J. Immunol. 160: 69-76 [Abstract] [Full Text]  
• Salk, J, Bretscher, P., Salk, P., Clerici, M, Shearer, G. (1993). A strategy for prophylactic vaccination against HIV. Science 260: 1270-1272  
• Fultz, P. N., Nara, P., Barre-Sinoussi, F., Chaput, A., Greenberg, M. L., Muchmore, E., Kieny, M.-P., Girard, M. (1992). Vaccine Protection of Chimpanzees Against Challenge with HIV-1-Infected Peripheral Blood Mononuclear Cells. Science 256: 1687-1690 [Abstract]  
• Wolinsky, S., Wike, C., Korber, B., Hutto, C, Parks, W., Rosenblum, L., Kunstman, K., Furtado, M., Munoz, J. (1992). Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 255: 1134-1137 [Abstract]  
• Wang, C., Looney, D., Li, M., Walfield, A., Ye, J, Hosein, B, Tam, J., Wong-Staal, F (1991). Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 254: 285-288 [Abstract]